autoimmune disease therapy (Aixlie)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameautoimmune disease therapy (Aixlie)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunosuppressants
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Ohio State University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAixlie Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A